After buying a portion of IFM Therapeutics’ pipeline in 2019, Novartis is back for a second helping as it bags its STING antagonists.
The Swiss Big Pharma had paid $90 million upfront a few years ago for an option and collaboration
agreement
and would pay up to $745 million in milestones if it opted to acquire IFM’s subsidiary IFM Due.
Its time is due, and the companies
said
Wednesday that Novartis will have full rights to IFM Due’s portfolio of STINGantagonists, which could turn into treatments for inflammation-driven diseases. The deal is a result of a four-year preclinical tie-up on small molecules.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.